CTCs gain character(ization)

Despite the recent shuttering of circulating tumor cell diagnostic company On-Q-ity Inc., researchers at Massachusetts General Hospital think there is still reason to innovate in the space. The group has developed a microfluidic platform able to identify circulating tumor cells that lack epithelial cell adhesion molecule.¹

Johnson & Johnson has rights to the technology and is funding development of the product, which is dubbed CTC-iChip, under a 2011 deal with MGH.²...